‘You have lives impacted across Illinois': State employees to lose Heath Alliance coverage over the summer
A spokesperson for Carle Health confirmed state employees will lose coverage over the summer since the contract ends on June 30th. But, she said this isn't atypical as the calendar runs July 1 through June 30 for many.
Several employees in Central Illinois use Health Alliance, such as 7,000 people at the University of Illinois Urbana-Champaign and many others in some school districts including Champaign and Mahomet-Seymour.
Health Alliance discontinuing plans at year's end; Medicare Advantage to continue
Teachers in Mahomet have mixed emotions about the news. One said she 'trusts the district to make the right move' when it comes to finding another program. The other said she is still in shock and is worried about other companies covering the medicine she takes daily.
Lawmakers like Sen. Chapin Rose (R-Mahomet) know it's a tricky situation to navigate.
'The first thing we have to do is make sure there are options and choices in open enrollment in May. People have to have a place to go and a place to go that includes their current provider,' he said. 'I do not want to go through one of these rounds where I have husbands calling me because their wife's in chemotherapy treatment and nobody knows if they're gonna be able to stay with their oncologist.'
Insurance expert breaks down implications of Health Alliance's discontinued services
Sen. Rose, and several others, want to know what insurance options people will have once May starts. Central Management Services (CMS) is the department that helps with insurance for state workers.
'Like so many others, CMS was not given advance notification of this decision by Health Alliance. State employees, retirees, and their dependents should know that the change in coverage is not immediate, and CMS is working diligently to make sure impacted individuals experience a smooth transition. CMS will communicate directly with impacted parties and ensure they are well informed of their options.'
Cynthia Johnson, Deputy Director
Carle Health said they are ready to help customers and provide resources to make sure it's a smooth transition to other providers. They said it was important to make sure people knew what was going on before open enrollment.
When Health Alliance closes, about 600 employees will lose their jobs. Carle Health will provide free training opportunities for employees to start new careers.
To learn more about when your plan may end, or with any other questions, visit this link for other background information.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
6 hours ago
- Business Insider
Warren Buffett Makes ‘No-Brainer' U-Turn Bet on UnitedHealth (UNH)
UnitedHealth Group (UNH), one of the largest insurance and health care services companies in the U.S., has had a tough start to 2025, with the company losing ~40% of its market value so far. However, Warren Buffett's Berkshire Hathaway (BRK.B) seems to have spotted a turnaround opportunity as the latest SEC filings revealed that Berkshire has scooped up over 5 million UnitedHealth shares in Q2, valued at close to $1.6 billion. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. After deconstructing the bear case for UnitedHealth, I believe the challenges facing the company are mostly transitory and, therefore, temporary. On the other hand, UnitedHealth is gearing up for price increases in 2026, setting the stage for margin expansion. I am Bullish on UnitedHealth as these findings suggest a mismatch between the economic reality for UnitedHealth and its market valuation. The Bear Case Rests On a Few Pillars Before laying out the case for my bullish outlook on UnitedHealth, it's crucial to first examine the bear thesis that has weighed heavily on the stock this year. The central issue is cost control—or rather, the lack of it. UnitedHealth has admitted to missteps in its pricing strategy, resulting in eroded margins. In its Q2 earnings release, management disclosed that medical costs are projected to run $6.5 billion higher than initially expected in 2025, according to TipRanks data. The Medical Care Ratio—representing the share of premiums spent on medical expenses—jumped 430 basis points year-over-year to 89.4%, a stark confirmation of mounting cost pressures. The Medicare Advantage business, UnitedHealth's profit engine, reveals an even deeper problem. Management badly underestimated cost trends. As CEO Stephen Hemsley admitted after Q2 results, 2025 plan pricing was set on the assumption of a 5% cost trend—only to be revised up to 7.5%. Looking ahead, 2026 looks worse still, with medical costs expected to spike another 10%. And the headwinds don't stop there. UnitedHealth is also grappling with collapsing margins in Optum Health, the looming threat of a DOJ investigation (as reported by The Wall Street Journal), and continued weakness in its commercial insurance segment. Aggressive Pricing in 2026 May Revive Earnings Growth My bullish outlook on UnitedHealth is anchored by several factors, with the most critical being the anticipated plan price hikes in 2026. On the Q2 earnings call, management emphasized that its 2026 pricing strategy will prioritize margin recovery. After underestimating medical costs in both 2024 and 2025, UnitedHealth now expects the Medicare Advantage cost trend to approach 10% next year—paving the way for meaningfully higher premiums compared to the current cycle. The company has also flagged upcoming adjustments to employer-sponsored plan pricing, signaling margin improvement in its commercial segment as well. The pressure from rising Medicare Advantage costs was already visible in Q2, with UnitedHealthcare's operating margin shrinking to 2.4% from 5.4% a year earlier. Yet, with aggressive repricing on the horizon, 2026 could mark a sharp rebound in margins—potentially setting the stage for a broader recovery in UNH stock. UnitedHealth's Scale Advantages Are Unmatched Beyond the upcoming pricing adjustments, UnitedHealth's massive scale—bolstered by the integration of Optum Health—further reinforces my bullish thesis. By the end of Q2, the company had a staggering U.S. membership base of more than 50 million, giving it powerful bargaining leverage in contract negotiations with hospitals and physicians. In total, UNH has put out over 400 million health-adjusted scripts in 2025, and is on course to breach the 1 billion mark by the end of the year. This scale is challenging to replicate and should allow UnitedHealth to keep costs structurally lower than peers, translating into more substantial returns on equity and, ultimately, premium valuation multiples in the market. Equally important, the Optum Health integration has created a competitive moat that most pure-play insurers cannot match. While rivals may compete on price, few possess an integrated care delivery platform of this scale. By marrying financing with care delivery, UnitedHealth has positioned itself as a differentiated insurer with access to vast patient data—an asset that can drive smarter pricing decisions and improved healthcare outcomes. Is UnitedHealth a Buy, Sell, or Hold? Wall Street analysts have taken a cautious stance on UnitedHealth given the numerous risks weighing on the business this year. Among 22 analysts covering the stock, the average price target stands at $314.55 —suggesting the shares are fairly valued at current levels with only 2.6% potential upside over the next twelve months. Despite no recent price target hikes on Wall Street, UnitedHealth has been attracting several high-profile investing gurus and funds. In addition to Berkshire, Lone Pine Capital, Michael Burry's Scion Asset Management, Jim Simons-founded Renaissance Technologies, and Eminence Capital added UnitedHealth stock to their portfolios in the second quarter, suggesting the stock is attractively valued. At a forward P/E of just 18, I also believe that this market leader's scale and growth potential have been ignored by the market due to short-term challenges. UNH Investors Prepare for Short-Term Pain and Long-Term Gain UnitedHealth shares saw a modest lift last week on news of Berkshire Hathaway's investment, but the stock remains down roughly 40% year-to-date. While the market continues to focus on the company's near-term headwinds, the outlook for 2026 is far brighter, supported by planned premium hikes that should drive margin recovery. That said, the looming DOJ investigation has the potential to reshape UnitedHealth's business profile and warrants close monitoring. Still, I believe the company is well-positioned to navigate regulatory pressures, which underpins my continued Bullish stance.


Business Insider
7 hours ago
- Business Insider
Why Is Bernstein Analyst Cautious on UnitedHealth Group Stock (UNH)?
UnitedHealth Group (UNH) stock continues to be under pressure, down more than 50% since mid-April. Wall Street remains concerned about the health insurance giant's rising medical costs and the potential impact on Medicare Advantage margins and near-term earnings. In a new research report today, Bernstein analyst Lance Wilkes lowered his price target to $377 from $594 on the stock. He cited weaker near-term growth and lower profitability in Medicare Advantage (MA) plans as key reasons for the reduction. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Analyst Cuts EPS Forecast on Slower MA Growth Wilkes trimmed his 2026 EPS forecast to $30.15 per share from $33.01. He highlighted several factors behind the revision. Wilkes expects slower MA membership growth in 2026, as the company focuses on keeping profits up rather than adding new members. He also noted that a higher medical loss ratio in 2025 is likely to reduce the MA margin to around 1%, creating a smaller earnings base for future growth. Wilkes also noted slower growth in OptumHealth, UnitedHealth's healthcare services unit that manages care and wellness programs. He said weaker Medicare Advantage membership could limit OptumHealth's expansion and revenue growth. Despite these concerns, he believes that the company still has a strong market position and is working to control its costs. It should be noted that recently, several top investors and hedge fund managers added to their stakes in this struggling health insurance giant, reflecting long-term confidence in the company. Buffett's Berkshire Hathaway (BRK.B) revealed a new $1.57 billion stake in UNH stock. Further, Michael Burry's Scion Asset Management bought calls on 350,000 shares. Is UNH a Good Buy Right Now? average UnitedHealth stock price target implies a 1.96% upside potential.
Yahoo
14 hours ago
- Yahoo
CORRECTION – Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
IRVINE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests that addresses unmet clinical needs, announced today corrections to the second paragraph of its press release under the same headline sent out on August 8, 2025. The corrected release follows: MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now available in the Western United States. This innovative diagnostic tool aims to enhance vascular health monitoring in the region. We are also pleased to announce that we are now in-network with Blue Cross Blue Shield of Arizona, allowing us to better serve this market. Additionally, we have secured contracts that enable the reimbursement of claims through United Healthcare, Aetna, Cigna, and Humana on a nationwide basis. These claims will be reimbursed on an out-of-network basis and apply to their PPO and Medicare Advantage plans. We are happy to share that the SmartVascular Dx test is also covered by Medicare. Why SmartVascular Should Be Your Go-To Test The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions that can significantly improve health outcomes. Furthermore, we would like to remind our partners that we have collaborated with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact mjjohnson@ 866.299.8998